N-(6-chloropyridin-3-yl)-4-fluorobenzamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3780776 |
| CHEMBL ID | 1454208 |
| SCHEMBL ID | 5214418 |
| MeSH ID | M0593072 |
| Synonym |
|---|
| VU0409859-1 |
| ZTZ240 , |
| AKOS005282280 |
| n-(6-chloropyridin-3-yl)-4-fluorobenzamide |
| CHEMBL1454208 |
| 325457-98-5 |
| gtpl7668 |
| SCHEMBL5214418 |
| MS-1427 |
| n-(6-chloranylpyridin-3-yl)-4-fluoranyl-benzamide |
| bdbm64871 |
| n-(6-chloro-3-pyridinyl)-4-fluorobenzamide |
| n-(6-chloro-3-pyridyl)-4-fluoro-benzamide |
| cid_3780776 |
| GB9 , |
| mfcd05669564 |
| n-(6-chloro-3-pyridinyl)-4-fluorobenzenecarboxamide |
| Q27089304 |
| EN300-24614875 |
| Z1123963190 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development." | ( N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. Amato, G; Antonio, B; Fritch, P; McNaughton-Smith, G; Mersch, T; Rigdon, GC; Roeloffs, R; Suto, MJ; Wickenden, AD, 2011) | 0.37 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 (µMol) | 66.0000 | 0.1200 | 4.0480 | 10.0000 | AID669436 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 (µMol) | 66.0000 | 0.1200 | 4.0480 | 10.0000 | AID669436 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| potassium voltage-gated channel subfamily KQT member 2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 3.6800 | 0.2300 | 61.1402 | 554.6400 | AID2443; AID2548 |
| Potassium voltage-gated channel subfamily KQT member 3 | Homo sapiens (human) | EC50 (µMol) | 0.9800 | 0.0400 | 1.5208 | 4.3800 | AID669435 |
| Potassium voltage-gated channel subfamily KQT member 2 | Homo sapiens (human) | EC50 (µMol) | 0.9800 | 0.0400 | 1.3227 | 4.3800 | AID669435 |
| Beta-secretase 1 | Homo sapiens (human) | Kd | 114.0000 | 0.0400 | 0.0400 | 0.0400 | AID1301518 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID669436 | Antagonist activity at KCNQ1/MINK expressed in CHO cells assessed as inhibition of KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting | 2011 | ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6 | N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. |
| AID1301518 | Binding affinity to BACE1 (unknown origin) by surface plasmon resonance spectroscopic analysis | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. |
| AID1301521 | Binding affinity to BACE1 (unknown origin) at 20 uM after 24 hrs by 19F NMR spectroscopic analysis in presence of N-(2-amino-2'-(5,6-dihydro-2H-pyran-3-yl)-5H-spiro[oxazole-4,9'-xanthene]-7'-yl)-5-chloropicolinamide | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. |
| AID1301520 | Binding affinity to BACE1 (unknown origin) at 20 uM after 24 hrs by 19F NMR spectroscopic analysis in presence of (S)-3-(2-amino-6-(3-methylpyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. |
| AID1870630 | Agonist activity at human KCNQ2 expressed in CHO cells assessed as increase in outward current at 10 uM at 50 mV by patch clamp electrophysiology method | 2022 | Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15 | General Pharmacological Activation Mechanism of K |
| AID1301525 | Inhibition of Cathepsin D (unknown origin) by fluorescence assay | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. |
| AID1301522 | Binding affinity to Cathepsin D (unknown origin) at 20 uM after 24 hrs by 19F NMR spectroscopic analysis | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. |
| AID669435 | Agonist activity at KCNQ2/KCNQ3 expressed in CHO cells assessed as increase in KCl-induced 86Rb+ efflux incubated for 10 mins prior to KCl-induction by liquid scintillation counting | 2011 | ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6 | N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. |
| AID1301523 | Binding affinity to Cathepsin D (unknown origin) at 20 uM after 24 hrs by 19F NMR spectroscopic analysis in presence of (S)-3-(2-amino-6-(3-methylpyridin-2-yl)quinolin-3-yl)-N-(3,3-dimethylbutyl)-2-methylpropanamide | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. |
| AID1301519 | Binding affinity to BACE1 (unknown origin) at 20 uM after 24 hrs by 19F NMR spectroscopic analysis | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||